PTLA Profile
Portola Pharmaceuticals, Inc (PTLA) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company's lead product, Andexxa, is a recombinant protein designed to reverse the anticoagulant effects of Factor Xa inhibitors in patients experiencing uncontrolled bleeding or undergoing emergency surgery.
As of February 25, 2023, the market capitalization of Portola Pharmaceuticals, Inc was approximately $5.8 billion.
Please note that investing in biopharmaceutical companies, especially those in the clinical stage, involves significant risks and should be thoroughly researched before making any investment decisions.
|
